The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura.
Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder due to autoantibody-induced destruction of platelets. Several forms of therapy have been used, including corticosteroids, splenectomy, danazol, and a variety of immunosuppressants. We studied the mechanism of action of some of these treatments by evaluating patients' platelet-associated autoantibodies (PAAb) and platelet count before and serially following therapy. Treatment with corticosteroids, splenectomy, cyclophosphamide, and combination chemotherapy resulted in a progressive decrease in PAAb associated with an improvement in the platelet count, and appeared to act by primarily affecting autoantibody production. Conversely, PAAb levels either remained stable or increased during vincristine or danazol therapy despite improvement in the platelet count, suggesting that the major effect of these agents was decreased platelet removal by the reticuloendothelial (RE) system.
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA.
K
K
Fujisawa
P
P
Tani
L
L
Piro
R
R
McMillan
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000378:metabolism*; D001792:Blood Platelets / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy*; D013156:Splenectomy; D014750:Vincristine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D001323:Autoantibodies; D014750:Vincristine; D003520:Cyclophosphamide; D003613:Danazol